US Food and Drug Administration's Approval of Aripiprazole Tablets With Sensor: Our Perspective

被引：4
|
作者：
Lee, Daniel J. [1 ]
Farchione, Tiffany R. [1 ]
Mathis, Mitchell V. [1 ]
Muniz, Javier [1 ]
Muoio, Brendan M. [1 ]
机构：
[1] US FDA, Div Psychiat Prod, Ctr Drug Evaluat & Res, Silver Spring, MD USA
来源：
JOURNAL OF CLINICAL PSYCHIATRY | 2018年 / 79卷 / 03期
关键词：
D O I：
10.4088/JCP.18com12255
中图分类号：
B849 [应用心理学];
学科分类号：
040203 ;
摘要：
[No abstract available]
引用
收藏
页数：2
相关论文
共 50 条
  • [1] US Food and Drug Administration drug approval summaries: Imatinib mesylate, mesna tablets, and zoledronic acid
    Cohen, MH
    Dagher, R
    Griebel, DJ
    Ibrahim, A
    Martin, A
    Scher, NS
    Sokol, GH
    Williams, GA
    Pazdur, R
    [J]. ONCOLOGIST, 2002, 7 (05): : 393 - 400
  • [2] US Food and Drug Administration and Design of Drug Approval Studies
    Woloshin, Steven
    Schwartz, Lisa M.
    Frankel, Brittney
    Faerber, Adrienne
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 312 (20): : 2163 - 2165
  • [3] US Food and Drug Administration approval of esketamine and brexanolone
    Cristea, Ioana A.
    Naudet, Florian
    [J]. LANCET PSYCHIATRY, 2019, 6 (12): : 975 - 977
  • [4] US Food and Drug Administration's perspective on aquaculture drug residues
    Oriani, JA
    [J]. XENOBIOTICS IN FISH, 1999, : 15 - 23
  • [5] US food and drug administration drug approval summary: Conversion of imatinib mesylate (ST1571; Gleevec) tablets from accelerated approval to full approval
    Cohen, MH
    Johnson, JR
    Pazdur, R
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (01) : 12 - 19
  • [6] Food and Drug Administration approval process for ophthalmic drugs in the US
    Lloyd, Rhea
    Harris, Jennifer
    Wadhwa, Sonal
    Chambers, Wiley
    [J]. CURRENT OPINION IN OPHTHALMOLOGY, 2008, 19 (03) : 190 - 194
  • [7] Transparency and Dermatologic Device Approval by the US Food and Drug Administration
    Ezaldein, Harib H.
    Scott, Jeffrey F.
    Yin, Emily S.
    Ventura, Alessandra
    DeRuyter, Nicholaas P.
    Leffell, David J.
    [J]. JAMA DERMATOLOGY, 2018, 154 (03) : 273 - 280
  • [8] Product Approval and Public Health at the US Food and Drug Administration
    Lurie, Peter
    Sharfstein, Joshua M.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 326 (24): : 2469 - 2470
  • [9] Vilazodone: Clinical Basis for the US Food and Drug Administration's Approval of a New Antidepressant
    Laughren, Thomas P.
    Gobburu, Jogarao
    Temple, Robert J.
    Unger, Ellis F.
    Bhattaram, Atul
    Dinh, Phillip V.
    Fossom, Linda
    Hung, H. M. James
    Klimek, Violetta
    Lee, Jee Eun
    Levin, Robert L.
    Lindberg, Cheri Y.
    Mathis, Mitchell
    Rosloff, Barry N.
    Wang, Sue-Jane
    Wang, Yaning
    Yang, Peiling
    Yu, Bei
    Zhang, Huixia
    Zhang, Li
    Zineh, Issam
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (09) : 1166 - 1173
  • [10] The US Food and Drug Administration's Perspective on the New Antidepressant Vortioxetine
    Zhang, Jing
    Mathis, Mitchell V.
    Sellers, Jenn W.
    Kordzakhia, George
    Jackson, Andre J.
    Dow, Antonia
    Yang, Peiling
    Fossom, Linda
    Zhu, Hao
    Patel, Hiren
    Unger, Ellis F.
    Temple, Robert J.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2015, 76 (01) : 8 - 14
12345